All simulators

Correcting a High

Still high an hour after a correction? Insulin is slow. See what a second dose, or a bigger first one, really does.

For learning only, not medical advice. Talk to your care team before changing your management.

Try these three

Blood sugar starts high and steady, above the high line, the upper of the two dashed lines, the top of the target range, and a correction dose goes in at 0:00. The Right size is enough on its own to bring blood sugar back into range, given time. You can make the first correction Bigger or Much bigger, and add a second dose later: None, Half, Same, or Double the first.

  1. Wait, or take a second dose an hour in

    With the Right size and no second dose, press Save curve. An hour in, blood sugar has barely moved. Now move the second dose’s Amount to Same. Blood sugar gets below the high line only a little sooner, then keeps falling, into a low.

  2. The right size, or a bigger first correction

    Save the curve for the Right size with no second dose, then pick Much bigger. In the first hour the two lines are close. After that they split: the bigger dose gets below the high line sooner, and keeps going, into a low.

  3. A later second dose

    With the Right size, move the Amount to Same and save the curve. Then move the Time to 2:00. A second dose that late barely gets blood sugar into range any sooner, and still takes it low.

What’s happening here?

An hour after a correction, blood sugar is often still high. That doesn’t mean the dose isn’t working. Insulin is slow, and most of its work is still to come.

  • Insulin is slow to start and slow to finish. Rapid-acting insulin’s effect peaked about 1½ hours after a dose in adults without diabetes,1 and about 2 hours after it in adults with type 1.2 So an hour after a correction, blood sugar has barely started to come down.
  • A second dose is slow too. A dose taken an hour in starts as slowly as the first did. It barely changes the next half hour, and gets blood sugar into range only a little sooner. Then it keeps working for hours after the first correction has done its job, and takes blood sugar low.
  • A bigger first dose is the same story. A bigger correction moves blood sugar only a little more in the first hour. It gets into range sooner, but the extra still keeps working for hours, and takes blood sugar low.
  • Stacking. A dose taken while an earlier one is still working stacks on top of it. A second dose taken out of frustration at a high that won’t come down is sometimes called a rage bolus. Insulin still working from an earlier dose that isn’t counted can lead to lows that are hard to explain.3
  • The other side of “more isn’t faster.” On Split Bolus, a high-fat meal shows the same idea from the food’s side. For a slow meal, when the insulin goes in matters more than how much.
  • Here, insulin is all that moves the line. Whatever made blood sugar high stays as it was, and the body’s own push back up out of a low isn’t shown. A real line can fall more slowly or more quickly than this one, and a real low can start to come back up on its own.

Try it on your own highs

The chart can’t know how your own corrections play out. A few weeks of notes can.

  1. Note each correction

    When you took it, and whether you took a second dose before the first had finished working.

  2. Note what blood sugar did next

    How much it had moved after an hour, how long it took to come down, and whether it went low hours later.

  3. Compare, then talk it through

    Highs corrected once and highs corrected twice tend to look different. Take what you find to your care team. They can tell you how long your insulin keeps working, and what to do when you’re still high.

Where the numbers come from

The chart is a model, set to match published studies. Here is where each part comes from.

  • The insulin. Every dose is rapid-acting insulin, on the same curve as the other simulators. It starts to work about 10 minutes after a dose and peaks at about 1¾ hours, between the studies’ numbers.1,2
  • The doses. The Right size is a correction for a usual body, sized to bring blood sugar back into range. Bigger is half as much again, and Much bigger twice as much. The second dose is half, as much again, or twice the first correction.
  • Insulin’s limit. Insulin can only lower blood sugar so fast.4,5 Only the biggest combinations here reach that limit, and the model lets what is over it work later. How the Simulators Work has the details.
  • What isn’t shown. Whatever made blood sugar high holds it there, so the sugar the kidneys pass at a high blood sugar is left out. So is the body’s own push back up out of a low. The biggest combinations fall off the bottom of the chart: a real low stops falling long before that.

These curves are typical examples. Every body is different. Use the simulators to understand how the factors work together, not to make decisions about managing your diabetes.

Sources

  1. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22(9):1501–1506. doi.org
  2. Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet. 2017;56(5):551–559. doi.org
  3. Walsh J, Roberts R, Heinemann L. Confusion regarding duration of insulin action: a potential source for major insulin dose errors by bolus calculators. J Diabetes Sci Technol. 2014;8(1):170–178. doi.org
  4. Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol. 1981;240(6):E630–E639. doi.org
  5. Grant M, Heise T, Baughman R. Comparison of pharmacokinetics and pharmacodynamics of inhaled Technosphere insulin and subcutaneous insulin lispro in the treatment of type 1 diabetes mellitus. Clin Pharmacokinet. 2022;61(3):413–422. doi.org